Targeting pancreatic cancer metastases with targefrin
Ended Project Grant Awarded Last action
- Award ID
- R43CA277917
- Recipient
-
Armida Labs Inc. UEI DXNPA5VKJM96
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $587,500
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Place of performance
- California, USA
Award details come from USAspending.gov.
Description
- Abstract
- We intend to devise a novel therapeutic strategy based on a specific cancer cell receptor named EPHA2, which is abundant on the surface of metastatic pancreatic cancers. Over the past several years our studies focused on testing the anti-cancer potential of agents targeting the receptor in suppressing cell migration and invasion in cellular studies, as well as in inhibiting tumor metastases using in vivo models. Very recently we have derived the most effective agonistic agent reported to date that potently targets the EPHA2 receptor and causes its degradation. In preliminary studies, the agent is remarkably effective in inhibiting pancreatic cancer cell migration. The agent also causes the internalization of the receptor; hence we intend to probe whether we can use this agent also to deliver chemotherapy selectively to pancreatic tumors.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $187,500 | |
| Original award | $400,000 |
Quick answers
Who received award R43CA277917?
R43CA277917 was awarded to Armida Labs Inc. by National Cancer Institute (National Institutes of Health) on September 14, 2023.
How much is award R43CA277917 worth?
$587,500 has been obligated on R43CA277917.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award